Strong Drive for Danish Biotechs


Copenhagen - Many years of strategic investments in life sciences and biotechnology have contributed to building up Denmark as a strong biotech nation. The Danish biotech sector is ranked among the best when comparing the quality of biotech research or the number of biotech patents per inhabitants with other OECD countries. Part of the Danish biotech/pharma industry is concentrated in the Medicon Valley region around Copenhagen and Malmö, Sweden, which is among the leading bio-tech regions in Europe with a unique concentration of universities, research institutions and industry. New initiatives such as bioTEAMsouth (Odense), the biomedical Science Park (Århus) and BioMed Community (Ålborg) are further examples of the growing development of the Danish bio-tech sector. The aim is that Denmark beco-mes even more attractive as an investment opportunity when foreign biotech companies are looking for new places for research and innovation activities. Thus the Government has introduced plans for a new foundation for high technology research and innovation, with biotechnology as one suggested focus area. The foundation will be launched on January 1, 2005. In 2012 its capital base will reach more than Euro2 billion. It is our intention to obtain synergy through private and institutional co-financing from national as well as international sources. Together with the Strategic Research Council, the foundation will be an important driver for Danish biotech research and development, minimizing the gap between research and innovative products.



Bagsværd – Net profit at Denmark’s Novo Nordisk A/S ballooned in the first six months of 2011, and the firm has raised guidance for the full year results. Sales rose by 9%, from DKK29.1bn to DKK31.7bn, while reported net profit...



Copenhagen – Driven by strong sales, Danish drugmaker Lundbeck A/S reported hefty QII/2011 profits, and says it is now expecting full-year results at the upper end of its guided range. Operating profit rose to DKK1.1bn in the...



Copenhagen - All is well in Denmark - for now. Danish Drugmaker Lundbeck reported excellent profits in the second quarter but announced its intention to prepare for deep cuts in research. 175 jobs in Denmark and the US (12.5% of...



Kvistgaard – Bavarian Nordic A/S of Denmark has raised DKK698m (EUR94m)through a rights issue to fund development of its prostate cancer vaccine Prostvac. A total of 12.9 million shares were sold at DKK54. The company announced...



Kvistgaard – Net loss at Danish biopharmaceutical company Bavarian Nordic A/S increased to DKK390m from DKK266m in the previous year, even though revenue grew to DKK314m, up from DKK75m in 2009. Bavarian Nordic’s lead product is...



Copenhagen – Despite recent setbacks, Danish TopoTarget A/S still has hopes for its histone deacetylase (HDAc) blocker belinostat (PXD01). The cytotoxic compound for treating lymphoma and solid tumours has failed to show...

Displaying results 11 to 20 out of 194

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues